Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice by Swelm, R van et al.
Identification of Novel Translational Urinary Biomarkers
for Acetaminophen-Induced Acute Liver Injury Using
Proteomic Profiling in Mice
Rachel P. L. van Swelm1, Coby M. M. Laarakkers2, Ellen C. van der Kuur3, Eva Morava-Kozicz4,
Ron A. Wevers2, Kevin D. Augustijn5, Daan J. Touw6, Maro H. Sandel7, Rosalinde Masereeuw1,
Frans G. M. Russel1*
1Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2Department of Laboratory Medicine,
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3 Streekziekenhuis Koningin Beatrix Ziekenhuis, Winterswijk, The Netherlands, 4Department of
Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 5Department of Chemistry and Pharmacochemistry, Vrije Universiteit, Amsterdam,
The Netherlands, 6Apotheek Haagse Ziekenhuizen, The Netherlands, 7Hagaziekenhuis, Den Haag, The Netherlands
Abstract
Drug-induced liver injury (DILI) is the leading cause of acute liver failure. Currently, no adequate predictive biomarkers for
DILI are available. This study describes a translational approach using proteomic profiling for the identification of urinary
proteins related to acute liver injury induced by acetaminophen (APAP). Mice were given a single intraperitoneal dose of
APAP (0–350 mg/kg bw) followed by 24 h urine collection. Doses of$275 mg/kg bw APAP resulted in hepatic centrilobular
necrosis and significantly elevated plasma alanine aminotransferase (ALT) values (p,0.0001). Proteomic profiling resulted in
the identification of 12 differentially excreted proteins in urine of mice with acute liver injury (p,0.001), including
superoxide dismutase 1 (SOD1), carbonic anhydrase 3 (CA3) and calmodulin (CaM), as novel biomarkers for APAP-induced
liver injury. Urinary levels of SOD1 and CA3 increased with rising plasma ALT levels, but urinary CaM was already present in
mice treated with high dose of APAP without elevated plasma ALT levels. Importantly, we showed in human urine after
APAP intoxication the presence of SOD1 and CA3, whereas both proteins were absent in control urine samples. Urinary
concentrations of CaM were significantly increased and correlated well with plasma APAP concentrations (r = 0.97;
p,0.0001) in human APAP intoxicants, who did not present with elevated plasma ALT levels. In conclusion, using this
urinary proteomics approach we demonstrate CA3, SOD1 and, most importantly, CaM as potential human biomarkers for
APAP-induced liver injury.
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Introduction
Drug-induced liver injury (DILI) is the leading cause of acute
liver failure and remains difficult to predict due to the lack of
adequate biomarkers [1]. Monitoring of hepatic function in
patients receiving drugs of risk is mainly based on measuring
serum liver enzymes such as alanine aminotransferase (ALT) [2].
These enzymes are not accurately predictive for DILI, because
they can be detected only after damage has been instigated [3]. In
addition, some drugs can increase plasma liver enzymes without
actually causing liver damage, such as diclofenac and methotrex-
ate [4,5]. Therefore, there is a need for biomarkers that can detect
DILI at the onset and can be used as a tool during drug
development and monitoring of patients [6]. Biomarkers predic-
tive for DILI that can be detected in urine could be of great value
to monitor patients on a regular basis in a non-invasive way. The
urinary proteome mirrors the protein pool present in blood, and
proteins related to pathologies, such as acute liver injury, can be
detected in urine [7,8]. Compared to blood, urine is well suited for
proteomic profiling as it contains less high abundant proteins that
can hamper biomarker detection [9]. Nevertheless, human sample
collection for biomarker assessment is difficult, because the overall
incidence of DILI is 10–15 cases in 100 000 patient years and the
incidence for any particular drug can range from 1 case in 10.000
to 1.000.000 patient years [10].
Acetaminophen (APAP) is an interesting model compound for
searching biomarkers related to acute DILI. APAP is metabolized
to its reactive metabolite N-acetyl-p-benzoquinone imine
(NAPQI), which is detoxified by conjugation to GSH. With high
dosages of APAP, the GSH pool is depleted allowing NAPQI to
bind to cellular macromolecules. Binding of NAPQI to mitochon-
drial proteins initiates the formation of reactive oxygen species and
peroxynitrite. It has been demonstrated that oxidative stress leads
to lipid peroxidation, mitochondrial dysfunction, disruption of
calcium homeostasis and eventually necrotic cell death [11,12].
Previous proteomics studies using rodent plasma and liver tissue
showed marked changes in the expression levels of various proteins
as a result of APAP-induced hepatotoxicity [13,14,15], including
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proteins involved in lipid/fatty acid metabolism, energy metabo-
lism, oxidative stress, calcium homeostasis and inflammation.
The goal of this study was to identify proteins in human urine
related to acute DILI. To this end, we implemented a translational
approach to identify urinary biomarkers for human DILI. By first
identifying proteins related to liver injury in urine of mice exposed
to the drug of interest, and subsequently searching for the
orthologous proteins in human urine, we aim to more efficiently
use the limited availability of human urine samples for biomarker
assessment. Here, we show carbonic anhydrase 3 (CA3), super-
oxide dismutase 1 (SOD1) and calmodulin (CaM) as potential
urinary biomarkers for APAP-induced liver injury in both mouse
and human.
Materials and Methods
Ethics statement
All experiments were approved by the local Animal Welfare
Committee of the Radboud University Nijmegen (RU-DEC 2008-
142 and RU-DEC 2009-101), in accordance with the guidelines of
the Principles of Laboratory Animal Care (NIH publication 86-23,
revised 1985).
Human sample collection was evaluated by the ethical
committee of the Radboud University Nijmegen Medical Centre
and the Hagaziekenhuis (Den Haag, the Netherlands) and they
concluded that the performed research was not conducted under
the regulations of the Act on Medical Research Involving Human
Subjects, because sample collection included non-invasive sam-
pling of urine and use of leftover plasma samples, taken for clinical
analysis. Moreover, samples were collected anonymously and no
clinically relevant or incriminating information were used. Written
informed consent, therefore, was not compulsory; however, oral
informed consent was obtained for all volunteers, patients and the
parents of the underage patient with acetaminophen intoxication,
which was not recorded to keep the procedure anonymous.
Animal experiment
Male FVB mice (Charles River, Germany; 22–28 g bw) were
housed under controlled conditions and randomly assigned to a
single i.p. injection of vehicle (saline, n= 19)) or 100 (n= 6), 225
(n= 18), 275 (n= 33) or 350 (n= 6) mg/kg bw APAP (A500 Sigma-
Aldrich Chemie B.V., Zwijndrecht, the Netherlands). As a
negative control, mice (n = 6) were treated with 350 mg/kg bw
3-acetamidophenol (AMAP; A7205, Sigma-Aldrich). After injec-
tion, mice were placed individually in metabolic cages (Techni-
plast, Germany GmbH) to collect 24 h urine samples, with water
and pulverized standard chow ad libitum. Protease inhibitors
(Complete Mini, Roche Diagnostics, Almere, the Netherlands)
were added to the urine, which was then centrifuged at 30006 g
for 10 min at 4uC. Subsequently, blood plasma was collected in
lithium-heparin tubes by eye extraction under isoflurane anesthe-
sia and animals were sacrificed by cervical dislocation. Urine
creatinine and plasma ALT levels were assessed by routine assays.
Human sample collection
First, a control master pool was created consisting of 24 urine
samples of both male and female volunteers between 18–65 years
of age. Next, we were able to collect urine of a severe APAP
intoxication, concerning a 5 year old girl of 12.5 kg bw that
ingested approximately 12 tablets of 500 mg APAP. We received
one urine sample collected upon hospital admission (urine sample
1) and one pooled urine sample composed of urine collected
previous to, during, and after N-acetyl cysteine treatment (urine
sample 2). Plasma liver enzymes were determined at hospital
admission (plasma sample 1) and within 24 h after admission
(plasma sample 2). Plasma liver enzyme values of both plasma
samples were substantially increased. Enzyme concentrations in
sample 1 and sample 2 were: ALT 8475 U/L and 9265 U/L
(reference value ,35), aspartate aminotransferase 16850 U/L and
18420 U/L (ref ,40), lactate dehydrogenase 16010 u/L and
Table 1. Demographics acute DILI patients.
Parameter Reference value APAP intoxicants DILI 1 DILI 2
Sex Female Female
N Female 7
N Male 1
Age 39 (617) 66 85
Plasma ALT (U/L) ,35 19 (67) 217 269
Plasma creatinine (mmol/L) 60–120 54 (618) 64 144
Use of alcohol No No
N Yes 1
N No 7
Use of other drugs Yes Yes
N Yes 3
N No 5
Other drugs used Diazepam
Ibuprofen
Coffeine
Amoxicillin and clavulanic acid
Omeprazol
Alprazolam
Zoldipem
Alendronic acid
Co-trimoxazol
Pantoprazol
Lercanidipine
Dipyridamol
Acetylsalicylic acid
Furosemide
Metoprolol
Mean values for the APAP intoxicants are represented as mean 6 SD.
doi:10.1371/journal.pone.0049524.t001
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17730 U/L (ref 110–295) and gamma glutamyl transpeptidase 63
U/L and 60 U/L (ref ,35), respectively.
In addition, plasma and urine samples were collected from 10
patients with suspected drug-induced acute liver injury that were
admitted to the emergency room at Radboud University Nijmegen
Medical Centre (Nijmegen, the Netherlands) and the Hagazie-
kenhuis (Den Haag, the Netherlands). The demographics of these
patients are shown in Table 1.
Histology
Hematoxylin and eosin staining was performed on liver paraffin
sections. Liver damage was evaluated by a qualified pathologist
and scored blinded of 10 images taken from each liver section
(106magnification). For each image the degree of centrilobular
necrosis was assessed by overlaying the images with a grid (Image
J, 3700‘2 pixels) and counting the intersections in necrotic areas.
Liver injury was reported as mean percentage of centrilobular
necrosis. Kidney paraffin sections were stained using Periodic Acid
Schiff staining.
Urine protein profiling with MALDI-TOF MS
Urine samples were normalized according to creatinine values
to reduce sample protein variation [16]. Based on the method of
Fiedler et al., urine samples were subsequently pretreated using
affinity beads to isolate specific fractions of the urine proteome,
before MALDI-TOF MS analysis [17]. We used weak cation
exchange (WCX) Macro-PrepH carboxymethyl support beads
(Bio-Rad Laboratories, Hercules, CA, USA) and Magnetic Beads
based Hydrophobic Interaction Chromatography 8 beads (C8;
Bruker Daltonics GmbH, Bremen, Germany), that bind positively
charged proteins and hydrophobic proteins, respectively. Synthetic
hepcidin-24 (Peptide International Inc., Louisville, KY, USA) was
used as internal standard (IS) to enable comparison between
samples. Of the prepared sample, 1 ml was applied to a MSP 96
polished steel MALDI target plate under nitrogen flow, followed
by two times 0.5 ml of 5 mg/mL a-cyano-4-hydroxy-cinnamic
acid in 50% ACN and 0.5% TFA. Mass-to-charge (m/z) spectra
were generated using MALDI-TOF MS (Microflex LT with
software flexControl Version 3.0, Bruker Daltonics) in positive,
linear ion mode and 350 laser shots. Initial laser power; 50% for
1–20 kDa and 60% for 10–160 kDa measurements, Laser
Attenuator; Offset 25% and Range 20%. Pulsed ion extraction
was set to 250 ns. Samples prepared with the WCX support beads
were measured in the 1–20 kDa mass range and those prepared
with the C8 beads were measured in both the 1–20 kDa and 10–
160 kDa mass range. Calibration was performed using protein
calibration standard I for 1–20 kDa measurements and protein
calibration standard II (both Bruker Daltonics) for 10–160 kDa
measurements.
Peptide and protein identification
Proteins were identified by using a MALDI linear ion trap mass
spectrometer (vMALDI LTQ; Thermo Fisher Scientific) and LC-
MS/MS (nLC LTQ FT Ultra MS; Thermo Fisher Scientific) as
described elsewhere [18,19]. Single C8 pretreated urine samples
were used to identify specific protein masses smaller than 4 kDa
directly with vMALDI LTQ. Proteins larger than 4 kDa were
identified using 1D-gelelectrophoresis with a 15% SDS gel and
silver-blue staining. Bands were excised and subjected to
reduction, alkylation and trypsin digestion before being measured
on the vMALDI-LTQ. For LC-MS/MS two pooled urine samples
were used to identify differentially excreted proteins between
control (n = 5) and APAP-induced liver injury (n = 5; plasma
ALT.5000 U/L). Urine samples were in-solution digested, after
reduction and alkylation. The digested samples were loaded on
stagetips for desalting and concentrating, and eluted to a final
volume of 20 mL, 8 mL of which was used for analysis. To avoid
contamination with polymers, an extra strong cation exchange
purification step was performed.
Database searches were performed using the Mus musculus
RefSeq36 protein database supplemented with known contami-
nant proteins. For vMALDI LTQ the data search was performed
using SEQUEST (v. 28 BioworksTM), for LC-MS/MS protein
identifications were extracted from the data by means of the search
program Mascot (v2.2; Matrix Science). The following modifica-
tions were allowed in the search: carbamidomethylation of
cysteines (fixed), oxidation of methionine (variable) and acetylation
of the N-terminus (variable). When appropriate, searches specified
tryptic specificity, allowing a single missed cleavage site. Additional
parameters for vMALDI LTQ were 1.4 Da precursor ion mass
tolerance and 1 Da fragment ion mass tolerance. For LC-MS/MS
precursor ion mass tolerance was set to 10 ppm, and fragment ion
mass tolerance was set to 0.8 Da. Proteins identified using
vMALDI LTQ were considered significant with a peptide
probability .1e-002, and a protein probability .1e-003. Valida-
tion of proteins identified using LC-MS/MS was performed by an
in-house developed script (PROTON) as described elsewhere [19].
Immunoprecipitation
Urine samples were pretreated with C8 beads and incubated
overnight with PBS and 0.1% Triton containing 2 mM CaCl2 and
CaM antibody at 4uC. Subsequently, magnetic beads that bind
IgG (MagnabindTM Protein G Magnetic beads, Thermo scientific,
Rockford USA) were added and incubated for two hours at RT.
After removal of the unbound fraction, proteins were eluted from
the beads using 50% ACN and 0.5% TFA. The eluted fraction
was measured using MALDI-TOF MS, as described. To correct
for non-specific binding to the magnetic IgG beads, a urine sample
was analyzed as described without CaM antibody.
Western blot
Urine samples were normalized to creatinine (mouse samples) or
protein concentration (human samples) before loading on a SDS
gel. Antibodies against CA3 (1:100), SOD1 (1:2000) and CaM
(1:1000) were purchased from Abcam (Cambridge, UK). The
following positive controls were used: recombinant human CA3
protein (Abcam), bovine SOD1 protein (Bruker Daltonics), and
recombinant Xenopus laevis CaM [20]. Image J software (1.42q,
Figure 1. APAP-induced liver injury and kidney histology in mice. Hematoxylin and eosin staining of representative liver slides from a
vehicle-treated mouse (A and C) and an APAP-treated mouse (B and D). Panels A and B show a 106magnification, and a 206magnification of the
framed area is given in panels C and D, respectively. Centrilobular necrosis can be observed in liver slides after APAP treatment. Plasma ALT levels (E)
and the percentage of centrilobular necrosis (F) increased significantly in mice receiving 275 and 350 mg/kg APAP. Periodic acid-Schiff staining of
representative kidney slides from a vehicle-treated mouse (G and I) and an APAP-treated mouse (H and J) show no difference in histology. Panels G
and H demonstrate a 206magnification and a 406magnification is given for the framed areas in panels I and J. The scalebar represents 200 mm in
the slides with 106magnification, 100 mm with 206magnification and 50 mm with 406magnification. ** P,0.01, *** P,0.001 compared to vehicle
treated mice. ALT: alanine aminotransferase; AMAP: 3-acetamidophenol; APAP: acetaminophen.
doi:10.1371/journal.pone.0049524.g001
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Figure 2. Urinary protein profiles of APAP-induced liver injury in mice. Representative urine protein profiles of m/z values versus peak
intensity illustrate an APAP dose-related increase in urinary protein excretion (A). ALT-dependent increases in protein peaks were observed in urine
samples pretreated with WCX beads or C8 beads (B). The protein masses of 15.9 kDa and 16.8 kDa are indicated by (I) and (II), respectively. Double
charged forms are indicated by (+2H). The correlation between the relative peak intensity of two representative urinary CA3 fragments (C & D), SOD1
(E), and CaM (F) and plasma ALT was determined using the Spearman’s rank correlation coefficient (r) in mice with APAP dose $275 mg/kg body
weight. ALT: alanine aminotransferase; APAP: acetaminophen; CA3: carbonic anhydrase 3; CaM: calmodulin; SOD1: superoxide dismutase 1; WCX:
weak cation exchange.
doi:10.1371/journal.pone.0049524.g002
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National Institutes of Health, USA) was used to measure signal
intensities on Western blot.
ELISA assay
CaM concentration in human urine samples was determined
using an ELISA assay (E90640Hu, Uscn Life Science, China)
according to manufacturer’s protocol. CaM concentrations were
normalized to urine creatinine concentration. Samples were
measured in duplicate.
Statistical analysis
Statistics were performed using GraphPad Prism 5.02 (La Jolla,
USA), unless indicated otherwise. A p-value of less than 0.05 was
considered statistically significant. Data was compared between
groups using one-way ANOVA with a post hoc multiple
comparisons test. Spectra generated with MALDI-TOF MS were
analyzed using flexAnalysis Version 3.0 and ClinProTools Version
2.2 software (both; Bruker Daltonics). Protein masses that differed
significantly between the treatment groups were indicated using a
Student’s t-test or Wilcoxon rank test, depending on normal
distribution. Relative peak intensities were calculated by dividing
protein peak intensity by the peak intensity of the IS.
Results
Dose-dependent acute liver injury by APAP
Exposing mice to APAP resulted in dose-dependent hepatotox-
icity, defined histologically as centrilobular necrosis (Figure 1A–D).
The percentage of necrosis and the plasma ALT values were
significantly increased after APAP administration compared to
control and AMAP (Figure 1E and 1F). There was substantial
Table 2. Proteins identified with vMALDI-LTQ.
Protein Protein Mass (Da) P (pro) Peptide sequence [M+H]1+ (Da)
D-dopachrome tautomerase 13068.8 3.5e-007 R.FFPLEAVVQIGK.K 1335.7096
K.FLTEELSLDQDR.I 1465.7169
R.LCAATATILDKPEDR.V 1673.8527
K.STEPCAHLLVSSIGVVGTAEQNR.T 2425.2140
Fatty acid binding protein 1 liver 14236.5 3.3e-007 K.AIGLPEDLIQK.G 1196.6885
K.YQLQSQENFEPFMK.A 1788.8261
K. SVTELN#GDTITNTMTLGDIVYK.R 2386.1694
PRED. Sim to superoxide dismutase 1 15974.8 9.7e-007 R.HVGDLGNVTAGK.N 1167.6117
R.VISLSGEHSIIGR.T 1367.7641
K.GDGPVQGTIHFEQK.A 1512.7441
Peroxiredoxin precursor 5 21883.5 1.2e-006 K.ATDLLLDDSLVSLFGNR.R 1848.9702
Glutathion-S-transferase p1 23594.1 7.8e-007 R.EAAQMDMVNDGVEDLR.G 1792.7840
K.FEDGDLTLYQSNAILR.H 1854.9232
K.ALPGHLKPFETLLSQN#QGGK.A 2136.1448
Glutathion-S-transferase a3 25344.3 1.5e-006 K.SHGQDYLVGNR.L 1245.5971
R.ADIALVELLYHVEELPPGVVDN#FPLLK.A 3022.6023
Glutathion-S-transferase m3 25685.0 2.9e-004 K.VTYVDFLAYDILDQ#YR.M 1994.9746
Glutathion-S-transferase m1 25953.1 1.1e-006 R.YTMGDAPDFDR.S 1287.5310
R.MLLEYTDSSYDEKR.Y 1749.8000
Carbonic anhydrase 3 29347.7 1.0e-007 R.VVFDDTYDR.S 1129.5160
K.GEFQILLDALDK.I 1361.7311
K.YAAELHLVHWNPK.Y 1577.8223
R.EKGEFQILLDALDK.I 1618.8687
K.HDPSLQPWSASYDPGSAK.T 1942.8930
K.YN#TFGEALKQPDGIAVVGIFLK.I 2381.2751
R.SLFSSAEN#EPPVPLVGNWRPPQPVK.G 2746.4199
Ketohexokinase 32719.5 3.4e-004 K.HLGFQSAVEALR.G 1327.7117
K.VVHIEGR.N 910.4894
Regucalcin 33385.5 4.4e-007 R.WDTVSNQVQR.V 1232.6018
R.VAVDAPVSSVALR.Q 1283.7318
R.HQGSLYSLFPDHSVK.K 1714.8547
R.HQGSLYSLFPDHSVKK.Y 1842.9497
R.YFAGTMAEETAPAVLER.H 1855.8895
For each protein identified by vMALDI-LTQ the protein mass and the protein probability (P(pro)) are given. The peptide sequences by which the protein was identified
are listed with their corresponding monoisotopic mass ([M+H]1+).
doi:10.1371/journal.pone.0049524.t002
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interindividual variability in the toxic response to the highest doses
of APAP reflected by the range in ALT values (40-29000 U/L)
and percentage of necrosis (0–87%). Hence, ALT values and
necrosis showed a strong intra-individual correlation. Renal tissue
was analyzed histologically to rule out APAP-induced nephrotox-
icity as a possible cause of altered urine proteome composition. We
did not observe any histological changes that indicated kidney
injury (Figure 1G–J).
Presence of SOD1, CA3 and CaM in urine is related to
APAP-induced liver injury in mice
After urine profiling, an increased abundance in protein peaks
was observed for mice treated with 275 and 350 mg/kg APAP
compared to control and AMAP (Figure 2A). In total, 66 protein
peaks in the WCX beads spectra, and 75 protein peaks in the C8
beads spectra were detected as significantly different between all
APAP treatments and control. These proteins presented with
increasing peak intensities in urine of mice with elevated plasma
ALT values (Figure 2B). Most protein peaks were only detectable
in urine of mice with relatively severe APAP-induced liver injury.
However, two proteins of 15.9 and 16.8 kDa, later identified as
SOD1 and CaM, respectively, were observed in the C8 beads
spectra at low plasma ALT levels.
The eleven differentiating proteins that were identified using
vMALDI LTQ are depicted in Table 2. LC-MS/MS analysis
confirmed the presence of these proteins and additionally retrieved
the identity of the 16.8 kDa protein, which was not found using
vMALDI-LTQ (Table 3). Besides SOD1 and CaM, also peak
intensities of fragments of CA3 correlated closely with plasma
ALT values (Figure 2C–F), and therefore these 3 proteins were
investigated further.
To confirm the presence of CA3 and SOD1 in urine by a
specific antibody, we used Western blot analysis, as shown in
Figure 3A. Whereas CA3 could be detected only in urine of mice
with high plasma ALT (.3500 U/L) values, SOD1 was associated
with minor elevations in plasma ALT (.100 U/L) and it gradually
amplified with increasing plasma ALT values. After measuring the
intensities of the SOD1 signal in the Western blot, linear
regression analysis showed a significant correlation between
urinary SOD1 and plasma ALT levels (Figure 3B). The third
potential biomarker, CaM, was confirmed with an immunocap-
ture assay, by which the 16.8 kDa peak was precipitated from C8
beads pretreated urine (Figure 3C), using a specific antibody
against CaM.
Urinary biomarkers identified in mice show potential for
human acute DILI
To assess the biomarker potential of the proteins identified in
relation to APAP-induced liver injury in mice, we analyzed urine
samples of a patient with a severe APAP intoxication for the
presence of CA3, SOD1 and CaM. Western blot analysis
identified in both urine samples CA3 and SOD1, whereas both
proteins were absent in the masterpool control sample (Figure 4A).
Note that the positive control for SOD1 is of bovine origin and has
a lower molecular weight than human SOD1. The concentration
of urinary CaM, as determined by ELISA assay, was 75615 pg/
mmol creatinine (mean 6 SD) in the masterpool control sample
and increased to 15065 pg/mmol creatinine in urine sample 1
and 34006250 pg/mmol creatinine in urine sample 2.
Of all urinary proteins identified in mouse urine, CaM was the
only protein found in urine of mice treated with a high dose of
APAP that did not have elevated plasma ALT. Therefore, CaM
could serve as an early biomarker for acute DILI. To further
evaluate the potential of urinary CaM as novel biomarker for
human acute DILI, we collected urine samples of patients that
were admitted to the emergency room with suspected acute DILI.
We collected urine of 8 patients with APAP intoxication and 2
patients with acute liver injury caused by other drugs, not
including APAP (DILI 1 and DILI 2; Table 1). Although the
patients with APAP intoxications did not show elevated plasma
ALT levels, urinary CaM concentration was increased compared
to the masterpool control sample and this increase correlated
significantly with plasma APAP concentration (Figure 4B). Fur-
thermore, urinary CaM concentration was increased in both
patients with acute DILI not caused by APAP, to 140 pg/mmol
creatinine in DILI 1 and 257 pg/mmol creatinine in DILI 2.
These two patients, unlike the APAP intoxicants, did have elevated
plasma ALT levels. To rule out acute kidney injury, plasma
creatinine concentrations were measured, which were not
increased in the APAP intoxicants and DILI 1, and only slightly
elevated in DILI 2 (Table 2).
Table 3. Proteins identified with LC-MS/MS.
Protein Reference
emPAI
APAP/C
Peptides
APAP/C
D-dopachrome tautomerase* gi|6753618|ref|NP_034157.1| 6.7 7
Fatty acid binding protein liver 1* gi|8393343|ref|NP_059095.1| 214.4 6
Superoxide dismutase 1 gi|45597447|ref|NP_035564.1| 5.9 2
Peroxiredoxin precursor 5 gi|6755114|ref|NP_036151.1| 48.6 8
Glutathion-S-transferase p1* gi|10092608|ref|NP_038569.1| 3.6 5
Glutathion-S-transferase a3* gi|31981724|ref|NP_034486.2| 3.0 5
Glutathion-S-transferase m1* gi|6754084|ref|NP_034488.1| 10.5 11
Carbonic anhydrase 3* gi|31982861|ref|NP_031632.2| 4.2 7
Ketohexokinase* gi|31982229|ref|NP_032465.2| 0.8 4
Regucalcin* gi|6677739|ref|NP_033086.1| 3.9 9
Calmodulin gi|6753244|ref|NP_033920.1| 2.3 2
For each protein the ratio in protein abundance (emPAI) and number of unique peptides between mice with APAP-induced liver injury (APAP) and control (C) are given.
Proteins completely absent in the control urine sample are indicated with *, in which case only the value for APAP is given.
doi:10.1371/journal.pone.0049524.t003
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Discussion
The present study was designed to identify novel biomarkers in
urine for acute DILI by using APAP as model compound.
Applying multiple proteomics techniques allowed us to identify
twelve proteins related to APAP-induced liver injury. For the first
time, we report the presence of CA3, SOD1 and CaM in urine to
be related to APAP-induced liver injury, of which CaM had never
been linked to liver injury before. Of these proteins, principally
SOD1 and CaM closely associated with plasma ALT, as observed
by proteomic profiling and antibody-based methods. CA3
fragments showed a good correlation with plasma ALT with
Figure 3. Identification of CA3, SOD1 and CaM in mouse urine.Western blots show the relation between urinary SOD1 and CA3, and plasma
ALT levels in individual mice (n = 13; panel A), of which urinary SOD1 intensity on Western blot was analyzed by linear regression analysis (B).
Immunoprecipitation demonstrated the specific protein profile of CaM, i.e. the mass peak for CaM at 16.8 kDa (CaM+H) and its double and triple
charged form (CaM+2H and CaM+3H), in mouse urine after APAP treatment (C). ALT: alanine aminotransferase; APAP: acetaminophen; CA3: carbonic
anhydrase 3; CaM: calmodulin; SOD1: superoxide distmutase 1.
doi:10.1371/journal.pone.0049524.g003
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proteomic profiling but this could not be confirmed using Western
blotting with a specific antibody for the whole protein. However,
CA3 as well as SOD1 and CaM were present in human urine
samples after APAP intoxication, and are, therefore, proposed as
potential urinary biomarkers for APAP-induced liver injury.
Urinary CaM concentration was increased in human APAP
intoxications and correlated well with plasma APAP concentra-
tion, whereas plasma ALT was not increased. This suggests that
CaM might be an early marker compared to plasma ALT.
Urinary CaM concentration was also elevated in two cases of
human DILI caused by drugs other than APAP, indicating that
CaM is not specific to APAP-induced liver injury, but rather to
acute hepatocellular injury.
High doses of APAP caused liver damage as indicated by an
increase in plasma ALT and centrilobular hepatic necrosis.
Despite the use of inbred mice, our data indicate that the animals
showed a differential response to APAP. This is most likely caused
by a variation in glutathione stores in individual mice, since our
mice were not fasted before APAP administration [21]. The
variation in hepatotoxic response allowed us to correlate urinary
protein levels to plasma ALT, a conventional biomarker of liver
injury.
A major advantage of our experimental design was that we
could profile proteins in urine collected in a controlled animal
study. Urine samples from patients are difficult to profile in search
for biomarkers, because they vary in many features. For example,
nutritional status, disease condition, and/or use of other drugs
may affect the urinary proteome. Using a translational approach,
we were able to identify potential biomarkers for APAP-induced
liver injury in mice and confirm the presence of these proteins in
human urine samples after APAP intoxication and DILI caused by
other drugs.
In mice, urine was collected during 24 h after APAP
administration, and plasma and liver tissue samples at 24 h after
exposure. We measured urine at one time point after APAP
administration, but still observed a strong association between
plasma ALT values and both SOD1 and CaM levels in urine
samples. Yet, we could not assess if these potential biomarkers are
excreted in urine early after the onset of injury. Nevertheless,
SOD1 has previously been reported to appear in rat urine as early
as 12 h after treatment with CCl4, another known hepatotoxic
chemical [22]. A disadvantage of urine collection during 24 h
could be that potentially interesting proteins are difficult to detect
because of dilution, particularly those excreted shortly after the
Figure 4. Detection of SOD1, CA3 and CaM in human urine samples. Presence of CA3 and SOD1 was assessed by Western blot in urine
samples of masterpool control (I), severe APAP intoxication sample 1 (II) and 2 (III) and a positive control (IV) (panel A). Using an ELISA assay, the
urinary concentration of CaM was correlated with plasma APAP concentrations using the Pearson correlation (r) test in patients with an APAP-
intoxication, but without elevated plasma ALT values (B). The open data point represents the masterpool control urine sample. ALT: alanine
aminotransferase; APAP acetaminophen; CA3: carbonic anhydrase 3; CaM: calmodulin; SOD1: superoxide dismutase 1.
doi:10.1371/journal.pone.0049524.g004
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onset of injury. In addition, some proteins may be unstable in
urine and only fragments rather than intact proteins can be
detected. This has likely occurred for CA3 in the present study.
Obviously, the kidney has a major influence on urine content
and approximately 70% of the proteins in urine originate from this
organ [23]. Since most proteins identified in this study are not
liver-specific, we investigated whether potential kidney injury by
APAP could have been a confounding factor. No signs of kidney
injury were observed after APAP treatment as determined by
histology and the absence of kidney injury markers (kidney injury
molecule-1 and neutrophil gelatinase associated lipocalin; data not
shown). We, therefore, assume that the proteins found in urine
after APAP-induced liver injury were not the result of kidney
injury, but were released from liver into blood and subsequently
excreted by the kidney. Most of the proteins identified in this study
were only found in mice with high plasma ALT values and do not
seem to be suitable as biomarker. Urinary CA3 and SOD1 showed
a good correlation with plasma ALT and probably are also leakage
markers of injured hepatocytes. The advantage over plasma ALT
is that these markers can be measured in patients non-invasively.
CaM proved to be the most promising biomarker, because the
protein was found in urine of mice treated with a high dose of
APAP that did not show elevated plasma ALT levels. This was also
observed in urine samples of human APAP intoxicants. Although
plasma ALT levels were not increased in these patients, plasma
APAP concentrations were high enough that liver injury was a
concern as indicated by the Rumack-Matthew normogram [24].
These data indicate that CaM has potential as predictive
biomarker for acute DILI and that a mechanism of hepatocyte
release other than leakage may be involved.
Most of the proteins that we detected in urine are involved in
intracellular processes related to APAP-induced liver injury
(Table 1 and 2) [25,26,27,28]. These process are not specific to
APAP and, accordingly, the biomarkers identified in this study are
most likely not specific to APAP, but rather to acute hepatocellular
injury. In line with this, urinary CaM concentration was also
increased in human cases of DILI not caused by APAP. Since
oxidative stress, mitochondrial damage and disrupted calcium
homeostasis play an important role in APAP-mediated hepato-
toxicity, it is not exceptional that we identified SOD1 and CaM as
proteins with biomarker potential. The involvement of superoxide
dismutases in APAP-induced liver injury has previously been
demonstrated by the increased toxicity of APAP in mice with
reduced activity of SOD2 [29,30]. The exact role of SOD1 in
APAP-mediated hepatotoxicity remains controversial as both
protective and damaging effects have been reported, but SOD1
nitration and reduction in SOD1 activity appear to be involved
[31]. A role for CaM in APAP-induced liver injury has not been
clearly described; however, CaM does play a key role in
maintaining intracellular calcium balance. Binding of NAPQI to
mitochondrial proteins can cause mitochondrial permeability
transition, after which mitochondrial Ca2+ is released into the
cytosol [32]. The cytosolic Ca2+ concentration is tightly regulated
and any excess Ca2+ will be effluxed via the plasma membrane
Ca2+ ATPase transporter (PMCA), using CaM as ultimate
cofactor [33]. However, the peroxynitrite formed during APAP-
induced oxidative stress can oxidize specific methionine positions
of CaM, after which CaM is no longer able to activate PMCA,
which results in reduced excretion of cytosolic Ca2+ [34]. Previous
studies showed decreased activity of PMCA during APAP-induced
liver injury [35]. With sustained high cytosolic Ca2+ concentra-
tions, Ca2+ will be translocated to the nucleus by CaM, where it
will cause DNA fragmentation and ultimately lead to cell death
[36]. CaM is thus involved in the initiating events of APAP-
induced liver injury and may, therefore, be a potential early
biomarker.
Based on these data, the next step would be to investigate the
dynamics of the suggested biomarkers on hepatic regulation and
excretion in urine with DILI, by including multiple time points of
measurement after drug administration. This will also allow better
comparison of the urinary proteins as non-invasive biomarkers
with the conventional plasma ALT measurements, including the
predictive value for DILI. Continuous urine sample collection of
patients with APAP-induced liver injury and DILI caused by other
drugs is needed to assess further the suitability of the biomarkers
suggested for acute DILI in general.
In summary, using a translational approach we identified CA3,
SOD1 and CaM as novel urinary biomarkers in relation to APAP-
induced liver injury in both mouse and human urine samples.
These results allow further clinical validation to assess their
applicability as non-invasive biomarkers for acute DILI.
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